Market research
PHIO Phio Pharmaceuticals Corp
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 14M
- P/E ratio
- Not available
- Analyst target
- 14
- Dividend yield
- Not available
- Beta
- 0.79
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US71880W5013
- Market cap
- 14M
- P/E ratio
- Not available
- Analyst target
- 14
- Dividend yield
- Not available
- Beta
- 0.79
About
About Phio Pharmaceuticals Corp
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the PHIO discussion.
5 years, 4 months ago
Phio Pharmaceuticals Corp is currently in a long term downtrend where the price is trading 21.7% below its 200 day moving average.
From a valuation standpoint, the stock is 96.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 48.0.
Phio Pharmaceuticals Corp's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 100.0% to $0 since the same quarter in the previous year.
Finally, its free cash flow fell by 2.9% to $-3M since the same quarter in the previous year.
Based on the above factors, Phio Pharmaceuticals Corp gets an overall score of 2/5.